



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 16 2000

TECH CENTER 1600/290

In re Application of )  
Richard G. Olsen, *et al.* )  
Serial No. 09/125,841 )  
Filed: January 19, 1999 )  
For: Cellular Immunotherapy )

Examiner Ronald B. Schwadron, Ph.D.  
Group Art Unit 1600

#121C  
Harry  
Nov. 17 2000

RECEIVED

NOV 16 2000

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

TECH CENTER 1600/290

**RESPONSE TO NOTICE OF SEQUENCE LISTING REQUIREMENTS  
AND AMENDMENT**

Sir:

Responsive to the outstanding Office action mailed on October 4, 2000 (paper no. 8), Applicants submit herewith a computer-readable copy of a Sequence Listing pursuant to 37 C.F.R. § 1.821, *et seq.*, and a paper copy to be added to the specification by amendment submitted on May 2, 2000. The below-signed attorney hereby attests to the fact that the "Sequence Listing" on the enclosed 3.5" computer diskette as submitted herewith is identical to the paper copy of the "Sequence Listing" added to the specification by amendment herein, pursuant to 37 C.F.R. § 1.821(f). By his signature below, the undersigned attests to the fact that no new matter is introduced into the specification by these amendments or this computer-readable copy of the instant Sequence Listing.

**REMARKS**

The replacement page submitted herewith comprises a Sequence Listing pursuant to 37 C.F.R. § 1.821 *et seq.* and the amendments to the specification are made to identify the nucleotide sequences as filed with the SEQ ID Nos. in the Sequence Listing.

Respectfully submitted,

Date: November 6, 2000

  
Jerry K. Mueller, Jr.  
Reg. No. 27,576  
MUELLER AND SMITH, L.P.A.  
MUELLER-SMITH BUILDING  
7700 Rivers Edge Drive  
Columbus, Ohio 43235-1331  
Tel.: 614-436-0600  
Fax: 614-436-0057  
email: patents@infinet.com